Zhejiang Tianyu Pharmaceutical Co., Ltd. Logo

Zhejiang Tianyu Pharmaceutical Co., Ltd.

300702.SZ

(1.5)
Stock Price

16,25 CNY

0.21% ROA

0.36% ROE

529.88x PER

Market Cap.

6.603.397.190,00 CNY

60.45% DER

0.26% Yield

0.51% NPM

Zhejiang Tianyu Pharmaceutical Co., Ltd. Stock Analysis

Zhejiang Tianyu Pharmaceutical Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (44%), which means it has a small amount of debt compared to the ownership it holds

2 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

3 PBV

The stock's PBV ratio (2.18x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

4 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (252) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

5 ROE

The stock's ROE indicates a negative return (-3.16%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-1.89%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

9 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

10 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Zhejiang Tianyu Pharmaceutical Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Revenue
Year Revenue Growth
2013 723.249.900
2014 777.349.724 6.96%
2015 840.085.268 7.47%
2016 1.082.338.823 22.38%
2017 1.188.282.809 8.92%
2018 1.466.956.381 19%
2019 2.110.595.680 30.5%
2020 2.587.395.711 18.43%
2021 2.545.009.527 -1.67%
2022 2.666.678.471 4.56%
2023 2.074.281.240 -28.56%
2023 2.527.270.111 17.92%
2024 2.279.562.676 -10.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2013 32.742.700
2014 31.076.059 -5.36%
2015 41.407.551 24.95%
2016 58.730.479 29.5%
2017 59.209.844 0.81%
2018 79.459.801 25.48%
2019 112.254.684 29.21%
2020 179.065.203 37.31%
2021 227.400.161 21.26%
2022 231.103.550 1.6%
2023 235.277.505 1.77%
2023 243.822.486 3.5%
2024 239.967.212 -1.61%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Zhejiang Tianyu Pharmaceutical Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 133.908.700
2014 36.524.988 -266.62%
2015 47.968.668 23.86%
2016 55.805.394 14.04%
2017 71.030.195 21.43%
2018 93.486.977 24.02%
2019 115.767.621 19.25%
2020 105.077.060 -10.17%
2021 139.849.035 24.86%
2022 126.512.336 -10.54%
2023 671.201.933 81.15%
2023 95.458.421 -603.14%
2024 -152.256.007 162.7%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Zhejiang Tianyu Pharmaceutical Co., Ltd. EBITDA
Year EBITDA Growth
2013 43.781.800
2014 96.495.792 54.63%
2015 139.061.602 30.61%
2016 231.957.607 40.05%
2017 240.221.261 3.44%
2018 306.816.377 21.71%
2019 812.916.744 62.26%
2020 878.179.397 7.43%
2021 471.462.550 -86.27%
2022 300.839.800 -56.72%
2023 225.153.681 -33.62%
2023 583.530.106 61.42%
2024 371.294.840 -57.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Gross Profit
Year Gross Profit Growth
2013 200.915.200
2014 220.571.245 8.91%
2015 276.546.195 20.24%
2016 405.340.476 31.77%
2017 449.213.011 9.77%
2018 590.688.388 23.95%
2019 1.184.193.811 50.12%
2020 1.336.386.812 11.39%
2021 932.809.584 -43.26%
2022 687.541.843 -35.67%
2023 846.127.784 18.74%
2023 990.048.372 14.54%
2024 706.085.396 -40.22%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Net Profit
Year Net Profit Growth
2013 33.588.400
2014 24.139.825 -39.14%
2015 50.354.815 52.06%
2016 122.337.689 58.84%
2017 100.182.148 -22.12%
2018 163.661.953 38.79%
2019 585.725.746 72.06%
2020 667.060.796 12.19%
2021 204.676.095 -225.91%
2022 -118.952.558 272.07%
2023 2.732.085 4453.91%
2023 27.359.257 90.01%
2024 50.791.616 46.13%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 0 0%
2016 1 0%
2017 0 0%
2018 1 0%
2019 2 100%
2020 2 50%
2021 1 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2013 -28.582.400
2014 452.792 6412.48%
2015 -47.835.905 100.95%
2016 57.304.209 183.48%
2017 -24.021.330 338.56%
2018 -101.315.583 76.29%
2019 73.733.938 237.41%
2020 116.127.201 36.51%
2021 -998.619.740 111.63%
2022 -575.711.404 -73.46%
2023 -26.563.156 -2067.33%
2023 -360.710.204 92.64%
2024 167.255.236 315.66%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2013 39.731.800
2014 80.438.316 50.61%
2015 14.751.417 -445.29%
2016 164.739.556 91.05%
2017 88.516.869 -86.11%
2018 78.572.392 -12.66%
2019 427.836.939 81.63%
2020 622.180.520 31.24%
2021 -262.230.037 337.27%
2022 -48.699.788 -438.46%
2023 0 0%
2023 -43.904.903 100%
2024 202.629.340 121.67%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2013 68.314.200
2014 79.985.523 14.59%
2015 62.587.322 -27.8%
2016 107.435.347 41.74%
2017 112.538.199 4.53%
2018 179.887.975 37.44%
2019 354.103.001 49.2%
2020 506.053.319 30.03%
2021 736.389.702 31.28%
2022 527.011.616 -39.73%
2023 26.563.156 -1883.99%
2023 316.805.302 91.62%
2024 35.374.104 -795.59%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Equity
Year Equity Growth
2013 453.677.200
2014 456.216.986 0.56%
2015 495.771.801 7.98%
2016 607.309.491 18.37%
2017 1.287.660.339 52.84%
2018 1.446.459.954 10.98%
2019 2.037.135.649 29%
2020 3.546.738.191 42.56%
2021 3.709.213.349 4.38%
2022 3.495.005.866 -6.13%
2023 3.487.771.350 -0.21%
2023 3.529.127.662 1.17%
2024 3.498.687.911 -0.87%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Assets
Year Assets Growth
2013 971.786.700
2014 1.084.886.327 10.43%
2015 1.326.352.111 18.21%
2016 1.515.028.110 12.45%
2017 2.106.652.190 28.08%
2018 2.629.319.938 19.88%
2019 2.840.227.797 7.43%
2020 4.889.568.135 41.91%
2021 5.800.601.655 15.71%
2022 6.415.749.761 9.59%
2023 6.338.123.767 -1.22%
2023 6.329.655.408 -0.13%
2024 6.321.011.866 -0.14%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Liabilities
Year Liabilities Growth
2013 518.109.600
2014 628.669.340 17.59%
2015 830.580.310 24.31%
2016 907.718.619 8.5%
2017 818.991.851 -10.83%
2018 1.182.859.984 30.76%
2019 803.092.148 -47.29%
2020 1.342.829.943 40.19%
2021 2.091.388.305 35.79%
2022 2.920.743.895 28.4%
2023 2.850.352.416 -2.47%
2023 2.800.527.746 -1.78%
2024 2.762.939.859 -1.36%

Zhejiang Tianyu Pharmaceutical Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
7.08
Net Income per Share
0.04
Price to Earning Ratio
529.88x
Price To Sales Ratio
2.71x
POCF Ratio
21.44
PFCF Ratio
51.52
Price to Book Ratio
1.89
EV to Sales
3.42
EV Over EBITDA
34.96
EV to Operating CashFlow
27.02
EV to FreeCashFlow
64.92
Earnings Yield
0
FreeCashFlow Yield
0.02
Market Cap
6,60 Bil.
Enterprise Value
8,32 Bil.
Graham Number
2.88
Graham NetNet
-2.86

Income Statement Metrics

Net Income per Share
0.04
Income Quality
24.71
ROE
0
Return On Assets
0
Return On Capital Employed
0.01
Net Income per EBT
0.28
EBT Per Ebit
0.84
Ebit per Revenue
0.02
Effective Tax Rate
0.68

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
-0.01
Gross Profit Margin
0.36
Operating Profit Margin
0.02
Pretax Profit Margin
0.02
Net Profit Margin
0.01

Dividends

Dividend Yield
0
Dividend Yield %
0.26
Payout Ratio
5.83
Dividend Per Share
0.05

Operating Metrics

Operating Cashflow per Share
0.9
Free CashFlow per Share
0.37
Capex to Operating CashFlow
0.58
Capex to Revenue
0.07
Capex to Depreciation
0.56
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
85.11
Days Payables Outstanding
101.71
Days of Inventory on Hand
433.24
Receivables Turnover
4.29
Payables Turnover
3.59
Inventory Turnover
0.84
Capex per Share
0.52

Balance Sheet

Cash per Share
1,23
Book Value per Share
10,35
Tangible Book Value per Share
9.05
Shareholders Equity per Share
10.17
Interest Debt per Share
6.31
Debt to Equity
0.6
Debt to Assets
0.33
Net Debt to EBITDA
7.22
Current Ratio
1.16
Tangible Asset Value
3,11 Bil.
Net Current Asset Value
0,11 Bil.
Invested Capital
3666780195
Working Capital
0,39 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,57 Bil.
Average Payables
0,42 Bil.
Average Inventory
1828990643.5
Debt to Market Cap
0.32

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Dividends
Year Dividends Growth
2018 0
2019 0 0%
2020 1 0%
2021 1 0%
2022 0 0%
2024 0 0%

Zhejiang Tianyu Pharmaceutical Co., Ltd. Profile

About Zhejiang Tianyu Pharmaceutical Co., Ltd.

Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, and anti-asthmatic series. It also provides fine chemicals and CMO services. The company was founded in 1993 and is based in Taizhou, China.

CEO
Mr. Yong Jun Tu
Employee
4.690
Address
Huangyan Jiangkou Chemical Dev Zn
Taizhou, 318020

Zhejiang Tianyu Pharmaceutical Co., Ltd. Executives & BODs

Zhejiang Tianyu Pharmaceutical Co., Ltd. Executives & BODs
# Name Age
1 Mr. Guo Rong Zhu
Deputy GM & Non-Independent Director
70
2 Ms. Yan Wang
Board Secretary & Deputy GM
70
3 Mr. Chuanliang Deng
Deputy GM & Non-Independent Director
70
4 Mr. Fujun Wang
Deputy General Manager
70
5 Mr. Yong Jun Tu
Chairman & GM
70
6 Ms. Xiujuan Wang
Financial Director
70

Zhejiang Tianyu Pharmaceutical Co., Ltd. Competitors